英国皇家药学院决定立即取消以色列制药公司泰瓦制药的年度会议赞助和参展资格，涉及金额为£15,000的合约。1这一决定是在亲巴勒斯坦活动人士施压下做出的。皇家药学院代表英国3.4万名药剂师，在审查后认为泰瓦制药的某些活动与自身价值观不符。1
这是继英国皇家护理学院上周做出相同决定后，第二个英国主要医疗机构与泰瓦制药划清界线。1皇家护理学院代表英国50万名护士。1泰瓦制药对该决定表示失望，声称医疗不应被政治化，同时强调该公司每天为全球超过1.5亿患者提供服务。1
泰瓦制药曾因多起监管违规面临罚款，包括2024年欧盟委员会处以的€462.6百万罚款、2023年向美国司法部支付的$2.25亿罚款，以及2016年与美国证交会和司法部达成的$5.19亿和解协议。1
The Royal Pharmaceutical Society has terminated its partnership with Israeli pharmaceutical company Teva, withdrawing its sponsorship and exhibition status at the organization's annual conference.1 The decision follows pressure from pro-Palestinian activists and comes as the second major UK healthcare institution to sever ties with the firm, after the Royal College of Nursing made the same move the previous week.1 The Royal Pharmaceutical Society, which represents 34,000 UK pharmacists, stated that its review found certain Teva activities incompatible with its values.1 The arrangement involved a contract valued at £15,000.1
Teva expressed disappointment with the decision, arguing that healthcare should not be politicized.1 The company noted that it serves more than 150 million patients globally each day.1 The pharmaceutical firm has faced significant regulatory penalties in recent years, including a €462.6 million fine from the European Commission in 2024,1 a $225 million settlement with the US Department of Justice in 2023,1 and a $519 million settlement with the US Securities and Exchange Commission and Department of Justice in 2016.1 The Royal Pharmaceutical Society has previously taken ethical stances on investments, having suspended funding in Russia-linked companies following the 2022 invasion of Ukraine.1
评论
还没有评论，欢迎留下第一条。